<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594239</url>
  </required_header>
  <id_info>
    <org_study_id>M930121002</org_study_id>
    <nct_id>NCT04594239</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital Hollow</brief_title>
  <official_title>Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital Hollow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Confirm the effectiveness of Belotero Balance® (+) Lidocaine injection for the&#xD;
           correction of volume loss in the infraorbital hollow (IOH) area by demonstrating&#xD;
           superiority to untreated control&#xD;
&#xD;
        -  Identify the incidence of adverse events (AEs) and serious adverse events (SAEs)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">April 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of responders at Week 8 on the Merz Infraorbital Hollow Assessment Scale (MIHAS)</measure>
    <time_frame>Week 8</time_frame>
    <description>The MIHAS is a 5-grade scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) score at Week 8, as assessed by the treating investigator</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) score at Week 8, as assessed by the subject</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACE-Q™ Satisfaction with Eyes scores and changes from baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) related to Belotero Balance</measure>
    <time_frame>From baseline to week 72-76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent serious adverse events (TESAEs) related to Belotero Balance</measure>
    <time_frame>From baseline to week 72-76</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Correction of Volume Loss in the Infraorbital Hollow Area</condition>
  <arm_group>
    <arm_group_label>Treatment, needle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment, cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated-control / delayed-treatment, needle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated-control / delayed-treatment, cannula</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Belotero Balance (+) Lidocaine, needle</intervention_name>
    <description>Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles</description>
    <arm_group_label>Treatment, needle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Belotero Balance (+) Lidocaine, cannula</intervention_name>
    <description>Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas</description>
    <arm_group_label>Treatment, cannula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Untreated-control / delayed-treatment, needle</intervention_name>
    <description>Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)</description>
    <arm_group_label>Untreated-control / delayed-treatment, needle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Untreated-control / delayed-treatment, cannulas</intervention_name>
    <description>Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)</description>
    <arm_group_label>Untreated-control / delayed-treatment, cannula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is a candidate for bilateral IOH treatment.&#xD;
&#xD;
          -  Has symmetrical right and left IOHs with the same MIHAS score of 2 or 3 (moderate or&#xD;
             severe), as assessed live by the blinded evaluator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior lower-eyelid surgery, including orbital or midface surgery, or a permanent&#xD;
             implant or graft in the midfacial region that could interfere with effectiveness&#xD;
             assessments.&#xD;
&#xD;
          -  Previous treatment with fat injections or permanent and/or semi-permanent dermal&#xD;
             fillers in the midfacial region.&#xD;
&#xD;
          -  Previous lower-eyelid and/or malar-region treatments with any dermal fillers (e.g.,&#xD;
             collagen, hyaluronic acid (HA), calcium hydroxyapatite, poly L-lactic acid (PLLA))&#xD;
             within the past 24 months.&#xD;
&#xD;
          -  Any other medical condition with the potential to interfere with the study outcome&#xD;
             assessments or compromise subject safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz North America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Art of Skin MD, Merz Investigational Site #0010444</name>
      <address>
        <city>Solana Beach</city>
        <state>California</state>
        <zip>92075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moradi MD Face Beautiful Inc., Merz Investigational Site #0010358</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroDerm / Atlanta Center for Clinical Research, Merz Investigational Site #0010446</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project Glammers, Merz Investigational Site #0010443</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Dermatology, Cosmetic &amp; Laser Surgery, Merz Investigational Site #0010442</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mariwalla Dermatology, Merz Investigational Site #0010445</name>
      <address>
        <city>West Islip</city>
        <state>New York</state>
        <zip>11795</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HKB Surgeons, Merz Investigational Site #0010447</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Centre for Laser &amp; Facial Surgery, Merz Investigational Site #0010353</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jose Raul Montes Eyes and Facial Rejuvenation, Merz Investigational Site #0010436</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

